This page shows the latest Bispecific antibody news and features for those working in and with pharma, biotech and healthcare.
cancers. In December 2022, its bispecific antibody, Lunsumio (mosunetuzumab-axgb), was approved by the FDA for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more
CytomX's pipeline currently comprises seven therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies and immune modulators such as cytokines and checkpoint inhibitors.
Biogen has reached an agreement with Genentech – a member of the Roche group – on the potential commercialisation of the investigational bispecific antibody, glofitamab, as part of the companies’ long-standing collaboration ... it the first and
inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. ... Elranatamab is an investigational, humanised B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), which targets both BCMA-expressing multiple myeloma
Summit Therapeutics (Summit) has announced a definitive agreement of its partnership with Akeso in a deal worth up to $5bn to in-licence its breakthrough bispecific antibody, ivonescimab. ... Recently presented phase 2 study results showed the PD-1/ VEGF
CytomX's pipeline currently comprises seven therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies and immune modulators such as cytokines and checkpoint inhibitors.
More from news
Approximately 6 fully matching, plus 61 partially matching documents found.
Finally, in multiple myeloma, a first-in-class bispecific T-cell engager antibody – talquetamab – is showing promise in heavily pre-treated patients.
One particular session on bispecific antibodies attracted huge interest, requiring multiple separate overflow areas to accommodate the crowds. ... relapsed multiple myeloma with talquetamab – a GPRC5D x CD3 bispecific antibody.
We are following a similar approach in lung cancer through an ongoing partnership to pursue a molecular diagnostic strategy for our early-stage investigational EGFR-MET bispecific antibody, which is being
In April last year, it achieved a very successful IPO on the US Nasdaq, generating $208m thanks to investor belief in its cancer-focused antibody-based pipeline. ... In addition to traditional antibodies, the pipeline also includes antibody drug
5, 500. Merus Labs (Canada). Incyte (US). Discovery collaboration. Biclonics bispecific antibody technology for up to 11 research programmes, including 2 in immuno-oncology. ... Not disclosed. Bispecific antibody technology. Exicure. Purdue. $790m. Not
More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.
late phase clinical trials. Before that, he was clinical research physician at Chugai Pharma Europe, where he led clinical development for a bispecific T-cell engaging antibody programme and other early
Previously, she held the position of senior vice president of drug discovery at F-star, overseeing all internal and collaborative bispecific antibody discovery programmes.
Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... Hewill oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent
Cambridge-based antibody research company F-Star has appointed Dr Neil Brewis as chief scientific officer. ... This appointment strengthens our experienced management team and supports F-star's strategy to lead the bispecific antibody space in
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...